68 Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study
Journal of Nuclear Medicine · 2023-07 · 64 (7) · 1043-1048
DOI: 10.2967/jnumed.122.265245 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 25.05.2023. Verfasst von Riccardo Mei und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; riccardo.mei@studio.unibo.it. Hauptthemen laut MEDLINE: Adenocarcinoma, Pancreatic Neoplasms, Quinolines. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
68Ga-fibroblast activation protein inhibitors (FAPIs) are promising radiotracers for cancer imaging, with emerging data in the recent years. Nonetheless, the interobserver agreement on 68Ga-FAPI PET/CT study interpretations in cancer patients remains poorly understood.
Methods
68Ga-FAPI PET/CT was performed on 50 patients with various tumor entities (sarcoma [n = 10], colorectal cancer [n = 10], pancreatic adenocarcinoma [n = 10], genitourinary cancer [n = 10], and other types of cancer [n = 10]). Fifteen masked observers reviewed and interpreted the images using a standardized approach for local, local nodal, and metastatic involvement. Observers were grouped by experience as having a low ( 300 studies; n = 5). Two independent readers with a high level of experience and unmasked to clinical information, histopathology, tumor markers, and follow-up imaging (CT/MRI or PET/CT) served as the standard of reference (SOR). Observer groups were compared by overall agreement (percentage of patients matching SOR) and Fleiss κ with mean and corresponding 95% CI. We defined acceptable agreement as a κ value of at least 0.6 (substantial or higher) and acceptable accuracy as at least 80%.
Results
Highly experienced observers agreed substantially on all categories (primary tumor: κ = 0.71; 95% CI, 0.71-0.71; local nodal involvement: κ = 0.62; 95% CI, 0.61-0.62; distant metastasis: κ = 0.75; 95% CI, 0.75-0.75), whereas observers with intermediate experience showed substantial agreement on primary tumor (κ = 0.73; 95% CI, 0.73-0.73) and distant metastasis (κ = 0.65; 95% CI, 0.65-0.65) but moderate agreement on local nodal stages (κ = 0.55; 95% CI, 0.55-0.55). Observers with low experience had moderate agreement on all categories (primary tumor: κ = 0.57; 95% CI, 0.57-0.58; local nodal involvement: κ = 0.51; 95% CI, 0.51-0.52; distant metastasis: κ = 0.54; 95% CI, 0.53-0.54). Compared with SOR, the accuracy for readers with high, intermediate, and low experience was 85%, 83%, and 78%, respectively. In summary, only highly experienced readers showed substantial agreement and a diagnostic accuracy of at least 80% in all categories.
Conclusion
The interpretation of 68Ga-FAPI PET/CT for cancer imaging had substantial reproducibility and accuracy among highly experienced observers only, especially for local nodal and metastatic assessments. Therefore, for accurate interpretation of different tumor entities and pitfalls, we recommend training or experience with at least 300 representative scans for future clinical readers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; riccardo.mei@studio.unibo.it.
- Nuclear Medicine Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
- German Cancer Consortium, Partner Site University Hospital Essen, and German Cancer Research Center, Essen, Germany.
- Department of Nuclear Medicine, University Hospital Erlangen, Erlangen, Germany.
- Department of Clinical Medicine, Aalborg University Hospital, Aalborg, Denmark.
Zitieren
APA
Mei, R., Kessler, L., Pabst, K. M., Weber, M., Schmidkonz, C., Rischpler, C., Zacho, H. D., Hope, T., Schwarzenböck, S. M., Allen-Auerbach, M., Emmett, L., Ferdinandus, J., Unterrainer, M., Schaarschmidt, B. M., Umutlu, L., Farolfi, A., Castellucci, P., Nanni, C., Telo, S., …, & Fendler, W. P. (2023). 68 Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study. Journal of Nuclear Medicine, 64(7), 1043-1048. https://doi.org/10.2967/jnumed.122.265245
Vancouver
Mei R, Kessler L, Pabst KM, Weber M, Schmidkonz C, Rischpler C, et al. 68 Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study. Journal of Nuclear Medicine. 2023;64(7):1043-1048. doi:10.2967/jnumed.122.265245
BibTeX
@article{Mei2023,
author = {Mei, Riccardo and Kessler, Lukas and Pabst, Kim M and Weber, Manuel and Schmidkonz, Christian and Rischpler, Christoph and Zacho, Helle Damgaard and Hope, Thomas and Schwarzenböck, Sarah M and Allen-Auerbach, Martin and Emmett, Louise and Ferdinandus, Justin and Unterrainer, Marcus and Schaarschmidt, Benedikt M and Umutlu, Lale and Farolfi, Andrea and Castellucci, Paolo and Nanni, Cristina and Telo, Silvi and Fanti, Stefano and Herrmann, Ken and Fendler, Wolfgang P},
title = {68 Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study},
journal = {Journal of Nuclear Medicine},
year = {2023},
volume = {64},
number = {7},
pages = {1043--1048},
doi = {10.2967/jnumed.122.265245}
}
EUVIMED